Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab versus placebo as adjuvant therapy after curative resection for hepatocellular carcinoma
CTR20182326Phase 3Active
- Sponsor
- Junshi Biosciences
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by Junshi Biosciences. Started Dec 2018; status: active.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20182326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182326.